Promising Phase 1b Trial Results for Actinium Pharmaceuticals’ Actimab-A in r/r AML Support Buy Rating

Maxim Group analyst Jason McCarthy has maintained their bullish stance on ATNM stock, giving a Buy rating on March 17.

Jason McCarthy’s rating is based on the promising data from Actinium Pharmaceuticals’ Phase 1b trial, which evaluated the combination of Actimab-A and CLAG-M in patients with relapsed/refractory acute myeloid leukemia (r/r AML). The trial results showed a median overall survival of 18.4 months for patients who had received one to two prior lines of therapy, which is a significant improvement compared to historical outcomes of 13.3 months in the pre-venetoclax era and approximately 2.4 to 4.6 months in cases of venetoclax failure.
Additionally, the trial demonstrated high complete remission rates with measurable residual disease negativity, achieving 75% overall, 83.3% in patients with TP53 mutations, and 100% in those who had prior venetoclax therapy. The data suggest a survival benefit and mutation-agnostic potential for Actimab-A, especially in a challenging patient population. The upcoming pivotal Phase 2/3 trial, which will compare the combination therapy to CLAG-M alone, further supports the Buy rating as it indicates continued progress and potential for positive outcomes.

According to TipRanks, McCarthy is an analyst with an average return of -18.6% and a 25.86% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Medicus Pharma Ltd, SELLAS Life Sciences Group, and Mesoblast.

In another report released on March 17, H.C. Wainwright also reiterated a Buy rating on the stock with a $4.00 price target.